To include your compound in the COVID-19 Resource Center, submit it here.

Ilaris canakinumab regulatory update

Novartis disclosed in its 2Q11 earnings that

Read the full 74 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE